This site is intended for health professionals only

UCB brings Neupro back to all patients in Europe


UCB announced that Neupro (rotigotine transdermal patch) can now be prescribed to all patients with idiopathic Parkinson’s disease in Europe and is newly available for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults. This follows the decision of the European Commission to lift treatment restrictions on Neupro in line with the recommendation of the European Medicines Agency (EMEA), issued on 29 May 2009.

“We are delighted that all patients with Parkinson’s disease in Europe can once again benefit from continuous drug delivery and the improvement in symptoms that is offered with Neupro and that, for the first time, people with RLS in Europe will also experience the advantages of this important treatment,” said Troy Cox, Senior Vice President CNS Operations, UCB.

Since June 2008, Neupro supply in Europe has been limited to patients already established on the drug while a new cold-chain storage and distribution system was developed to meet the need for refrigeration of the product from manufacturer to patient. Following full implementation of this system, refrigerated stocks of Neupro are available in all doses so Neupro can be prescribed by European physicians for all patients with idiopathic Parkinson’s disease.

Parkinson’s disease affects over six million people worldwide and approximately three million patients in the seven major markets (US, Japan, Germany, UK, France, Italy and Spain). Formulated as a once-a-day transdermal patch, Neupro continuous drug delivery provides stable drug levels in the bloodstream.

Neupro provides statistically significant and clinically relevant improvements in movement and ability to carry out everyday activities in people with early-stage Parkinson’s disease and significantly reduces off time and increases on time in people with later stage Parkinson’s disease. Neupro is generally well-tolerated. Adverse drug reactions reported in more than 10% of Parkinson’s patients treated with Neupro are nausea, dizziness, somnolence and application site reactions.

In August 2008, the European Commission approved Neupro for the symptomatic treatment of idiopathic moderate to severe RLS in adults. The UK and Germany are the first European countries to launch Neupro (1 mg/24 h, 2 mg/24 h and 3 mg/24 h) in this new indication.

RLS affects between 3 and 10% of the population to some extent. In a clinical trial of 458 patients with moderate to severe RLS, Neupro (1 mg/24 h, 2 mg/24 h and 3 mg/24 h dose) proved more efficacious than placebo in relieving bedtime, night and daytime symptoms in patients over a six month treatment period. Neupro was shown to reduce symptoms by >=50% in over half of patients (54.2%) compared to symptom reduction in approximately one third (29.9%) of patients on placebo. In addition more patients receiving Neupro (3 mg/24 h) achieved clinical remission (47.3% vs. 22.8% placebo) and symptom freedom (31.3% vs. 12.3% placebo).

“We look forward to having Neupro available as a new treatment option for RLS patients. The results of this rotigotine trial demonstrated efficacy, increased opportunity for symptom freedom in moderate to severely affected RLS patients and improvements to patients’ quality of life” said Dr Claudia Trenkwalder from the Paracelsus-Elena Hospital, Kassel, Germany and lead investigator of the study.


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine